Results of a Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-Group Study of the Effi cacy and Safety of Mexidol in Prolonged Sequential Therapy of Patients in the Acute and Early Recovery Stages of Hemispheric Stroke (the EPICA study)

This article is in "Library" section.

Author:

L. V. Stakhovskaya1, N. A. Shamalov1, D. R. Khasanova2, E. V. Mel’nikova3, A. S. Agaf’ina4, K. V. Golikov5, E. I. Bogdanov6, A. A. Yakupova6, L. V. Roshkovskaya7, L. V. Lukinykh8, T. M. Lokshtanova9, I. E. Poverennova10, and L. A. Shchepankevich11

1 Research Institute of Cerebrovascular Pathology and Stroke, Pirogov Russian National Research Medical University, Russian Ministry of Health, Moscow, Russia; e-mail: lstakh@mail.ru.

2 Interregional Clinical Diagnostic Center, Kazan, Russia.

3 St. Petersburg City Clinical Hospital No. 26, St. Petersburg, Russia.

4 St. Petersburg City Clinical Hospital No. 40 of the Resort Administrative District, St. Petersburg, Russia.

5 St. Petersburg City General Hospital No. 2, St. Petersburg, Russia.

6 Kazan Sate Medical University, Russian Ministry of Health, Kazan, Russia.

7 Nikolaevskaya Hospital, St. Petersburg, Russia.

8 Vsevolzhsk Clinical Interregional Hospital, Leningradskaya Oblast, Russia.

9 Pirogov City Clinical Hospital No. 1, Samara, Russia.

10 Seredavin Samara Regional Clinical Hospital, Samara, Russia.

11 Research Institute of Experimental and Clinical Medicine, Novosibirsk, Russia.

Read more.


Mexidol® and Mexidol® FORTE 250: Just Go Ahead to New Efficacy and Safety Data!

LLC “Scientific Production Company “PHARMASOFT”, the owner of intellectual property for Mexidol® and Mexidol® Forte 250 reference (original) drugs, announces that it has obtained permission to conduct international randomized trials:

- A prospective international multicenter, randomized, double blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of Mexidol® intravenous and intramuscular administration solution, 50 mg/ml, and 250 mg film-coated tablets Mexidol® FORTE with their sequential use in patients with acute and early restorative periods of ischemic stroke. Record No. PHS-APIS-004-MEX-SOL-TAB of 21.06.2019.

- An international multicenter, randomized, double blind, placebo-controlled, adaptive design study to evaluate the efficacy and safety of sequential therapy with Mexidol® solution for intravenous and intramuscular administration, 50 mg/ml, and Mexidol® FORTE 250 film-coated tablets, 250 mg in patients with chronic brain ischemia. Record No. PHS-CICADIS-005-MEX-SOL-TAB of 08.08.2019.


The effect of mexidol in the combination with antidepressants on sleep disturbance in young patients with panic disorder

This article is in "Library" section.

Author:

E.S. KURASOV, R.S. REMIZEVICH
Kirov Academy of Military Medicine, St.-Petersburg

Read more.


The use of mexidol in urgent treatment of alcoholic delirium

This article is in "Library" section.

Author:

O.I. KLINDUKHOVA, O.E. NOVGORODOV, N.N. SERGIENKO, P.V. DANILYUK, O.V. BELOTSERKOVICH

Read more.


Combined administration of mexidol with known medicines

This article is in "Library" section.

Author:
T.A. VORONINA, E.A. IVANOVA

Research Zakusov Institute of Pharmacology, Moscow, Russia

Read more.


Pharmacoeconomic analysis of the neuroprotective medicines in the treatment of ischemic stroke

This article is in "Library" section.

Author:

R.I. YAGUDINA1, A.YU. KULIKOV1, V.A. KRYLOV1, E.YU. SOLOVIEVA2, A.I. FEDIN2

1 Sechenov First Moscow State Medical University, Ministry of Health of Russia, Moscow, Russia;
2 Pirogov Russian National Research Medical University N.I.Pirogov Russian National Research Medical University of the Ministry of Health
of Russia, Moscow, Russia

Read more.


Evaluation of blood rheology by patients with acute ischemic stroke with Mexidol administration

This article is in "Library" section.

Author:

D.M. PLOTNIKOV1, M.N. STEGMEIER1, O.I. ALIEV2

1 Department of Neurology and Neurosurgery, Siberian State Medical University, Tomsk, Russia;
2 Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center, Russian Academy of
Sciences, Tomsk, Russia

Read more.


New Packaging: Mexidol® 5 ml #10 and Mexidol® 2 ml #20

The new packages are designed for the minimum recommended therapeutic course and have been released to meet the needs of patients who have been prescribed Mexidol®.

The new packages will improve patients' adherence (compliance) to the prescribed therapy in order to increase its effectiveness.

Important! In order to maximize the therapeutic potential of Mexidol®, it is necessary to prescribe adequate therapeutic doses and follow the therapy sequence - to start treatment with injection form and then continue the treatment with tablets (Mexidol® film-coated tablets, 125 mg, and Mexidol® Forte 250 film-coated tablets, 250 mg).


Effect of mexidol on the efficiency of intravenous thrombolytic therapy for ischemic stroke during the therapeutic window

This article is in "Library" section.

Author:

Knni K.S., Dyomin T.V., Adeeva L.B.
Interregional Clinical and Diagnostic Center, Kazan, Russia 12A, Karbyshev St., Kazan, Republic of Tatarstan 420101

Read more.


Influence of mexidol and hemisuccinate 2-ethyl-6-methyl-3-hydroxypyridine on cerebral hemodynamics at hemorrhagic and ischemic damage of brain

This article is in "Library" section.

Author:
I.N. KURDYUMOV1, T.S. GAN,SHINA1, D.V. MASLENNIKOV1, E.V. KURZA1, A.A. GORBUNOV1,2, A.I. TURILOVAand R.S. MIRZOYAN1

V.V. Zakusov State Institute of Pharmacology, Russian Academy of Medical Sciences, Moscow, ul. Baltiiskaya 8, Moscow. 125315 Russia

I.M. Sechenov First Moscow State Medical University (Sechenov University), ul. Trubetskaya 8, Moscow, 119881 Russia

Read more.